HilleVax's stock tumbles after Phase 2b norovirus vaccine fails in infants
Takeda spinout HilleVax’s stock $HLVX sunk over 85% on Monday morning after the company announced its norovirus vaccine candidate failed a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.